Postoperative Nausea and Vomiting After Minimally Invasive Wedge Resection of the lung
Conditions
Interventions
Aprepitant group:One hour before anesthesia induction, intravenous bolus injection of 32mg Aprepitant, equivalent to 4.4ml of Aprepitant, mixed with 5.6ml of 0.9% Sodium Chloride Solution, for a total
Ondansetron group:One hour before anesthesia induction, intravenous bolus injection of 4mg Ondansetron, equivalent to 2ml of Ondansetron, mixed with 8ml of 0.9% Sodium Chloride Solution, for a total v
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 80 years; 2. Patients planning to undergo elective minimally invasive (VATS or RATS) wedge resection of the lung; 3. Patients scheduled to receive general anesthesia; 4. American Society of Anesthesiologists (ASA) physical status I-II; 5. Body Mass Index (BMI) between 18 and 28 kg/m² [BMI = weight(kg) / height(m)²].
Exclusion criteria
Exclusion criteria: 1. Patients with a history of previous general anesthesia; 2. Patients with a history of previous thoracic surgery; 3. Patients who have received systemic antineoplastic drug therapy in the past; 4. Patients undergoing surgeries other than wedge resection, such as segmentectomy, lobectomy, sleeve resection, etc.; 5. Patients undergoing open surgery; 6. Patients undergoing simultaneous bilateral lung wedge resection; 7. Pregnant or breastfeeding patients; 8. Patients with allergies to any of the study medications; 9. Patients who have received any sedatives, opioids, steroids, or antiemetic drugs within 24 hours before surgery; 10. Patients with a preoperative Visual Analogue Scale (VAS) score for nausea greater than 4 out of 10; 11. Patients currently taking or planning to combine medications such as rifampicin, carbamazepine, phenytoin, or other strong inducers of CYP3A4 activity; 12. Patients with moderate to severe liver dysfunction; 13. Patients who will receive anesthesia maintenance with propofol during surgery; 14. Patients undergoing routine placement of nasogastric or orogastric tubes during surgery; 15. Patients who are currently participating in or planning to participate in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The complete remission rate of no vomiting and no rescue within 24 hours postoperatively.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The complete remission rate of no vomiting and no rescue within 48 hours postoperatively.;The rate of no vomiting within 24 hours;The rate of no vomiting within 48 hours;The rate of no rescue within 24 hours;The rate of no rescue within 48 hours;The time to first occurrence of nausea or vomiting.;The severity of nausea within 24 hours postoperatively.;The severity of nausea within 48 hours postoperatively.;The longest duration of nausea within 24 hours postoperatively.;The longest duration of nausea within 48 hours postoperatively.;Postoperative vomiting frequency within 24 hours;Postoperative vomiting frequency within 48 hours;Length of hospital stay;Time to extubation; | — |
Countries
China
Contacts
Public ContactFang Wentao
Shanghai Chest Hospital
Outcome results
None listed